SCHEMBL3310055

SCHEMBL3310055

O=C(O)C(O)=CC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
MAPT P10636 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.58
TSHR P16473 1/20 0.58
CASP1 P29466 1/20 0.58
ERCC5 P28715 1/20 0.51
FEN1 P39748 1/20 0.51
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
MAPK1 P28482 1/20 0.49
HIF1A Q16665 1/20 0.49
SRD5A2 P31213 1/20 0.47
KDM4E B2RXH2 2/20 0.47
TP53 P04637 1/20 0.44
HPGD P15428 2/20 0.44
POLB P06746 2/20 0.44
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HTT P42858 2/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310052 1.00 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3310049 1.00 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3311027 0.86 ALDH1A1 (0.58) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3311029 0.86 ALDH1A1 (0.58) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3308122 0.86 ALDH1A1 (0.58) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3312420 0.84 FLT1 (0.44) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3312425 0.84 FLT1 (0.44) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3312429 0.84 FLT1 (0.44) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL34470516 0.83 CXCL12 (0.44) ALDH1A1MAPTSMN1; SMN2TSHRCASP1
SCHEMBL3311844 0.82 ALDH1A1 (0.60) ALDH1A1MAPTSMN1; SMN2TSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US claimed
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US disclosed
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US disclosed
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof TEXAS A&M UNIVERSITY SYSTEM, THE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof ME3, ME1, MDH1 ALDH1A1 620/4885MAPT 1964/4885SMN1; SMN2 4781/4885
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof ME3, ME1, MDH1 ALDH1A1 620/4885MAPT 1964/4885SMN1; SMN2 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.